Better Medicines Created Rapidly Through De Novo Protein Design

  • Demonstrating that miniproteins are a powerful, stable therapeutic modality with high-affinity, specific binding
  • Discussing development using a combination of de novo design, synthetic biology, and laboratory automation
  • Creating a toolbox of modular miniprotein domains with ideal drug-like and developability profiles